Immunotope was awarded a Phase II SBIR contract from the U.S. Army to develop an autoantibody-based early-stage diagnostic test for prostate cancer. The two-year, $780,000 award will fund the development of a noninvasive, highly sensitive, and selective blood test.
“Our test is based on the detection of autoantibodies, an immune response that is stimulated by the earliest presence of cancer in the patient’s body that does not occur in healthy individuals,” explains ” Ramila Philip, president and CSO. “We have identified prostate cancer-specific autoantibody signatures, which are biomarkers that we are using to create an accurate and sensitive blood test to diagnose the presence of prostate cancer long before it can be detected by current methods.”
Immunotope reports that its test will be fully compatible with commercial clinical diagnostic formats and ready for large-scale clinical testing as part of the FDA 510K marketability approval process at the end of the Phase II program.